

2018-10-01

Theobromine and related methylxanthines as inhibitors of Primary Amine Oxidase

Padraig Shanahan

Technological University Dublin, padraigshanahan@icloud.com

Jeffrey O'Sullivan

Trinity College Dublin, JOSULLI@tcd.ie

Keith Tipton

Trinity College Dublin, ktipton@tcd.ie

See next page for additional authors

Follow this and additional works at: <https://arrow.tudublin.ie/schfsehart>



Part of the [Biochemistry, Biophysics, and Structural Biology Commons](#), [Biology Commons](#), and the [Biotechnology Commons](#)

Recommended Citation

Henehan, G. et al. (2018) Theobromine and related methylxanthines as inhibitors of Primary Amine Oxidase, *J Food Biochem.* 2018;e12697.

This Article is brought to you for free and open access by the School of Food Science and Environmental Health at ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie.



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 4.0 License](#)
Funder: Technological University Dublin

Authors

Padraig Shanahan, Jeffrey O'Sullivan, Keith Tipton, Gemma Kinsella, Barry Ryan, and Gary Henehan

1 **Theobromine and related methylxanthines as inhibitors of Primary Amine Oxidase**

2 **Padraig Shanahan^a, Jeff O'Sullivan^b, Keith F Tipton^c, Gemma K Kinsella^a, Barry J Ryan^a,**
3 **Gary TM Henehan^{a,d}**

4 a. Applied Enzymology Group, School of Food Science and Environmental Health, College of Science and Health, Dublin
5 Institute of Technology, Dublin 1, Ireland.

6 b. School of Dental Science, Trinity College Dublin, Dublin Ireland.

7 c. School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.

8 d. Corresponding author

9

10 Padraig Shanahan, School of Food Science & Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland.

11 Phone: +353-1-402 4408, Email: padraig.shanahan@dit.ie

12 Dr Jeff O'Sullivan, School of Dental Science, Trinity College Dublin 2. Ireland Phone: (Bio): +353 1 896 1803 or (Dent): +353
13 1 613 7385 Email: josulli@tcd.ie

14

15 Professor Keith F Tipton, School of Biochemistry and Immunology, Trinity College Dublin 2, Dublin, Ireland. Phone: + 353-1-
16 896 1802. Email: ktipton@tcd.ie,

17 Gemma Kinsella, School of Food Science & Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland. Phone
18 +353 1 402 Email: gemma.kinsella@dit.ie

19 Dr Barry Ryan, School of Food Science & Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland. +353 1
20 402 4379, Email: barry.ryan@dit.ie

21 Dr Gary Henehan, School of Food Science & Environmental Health, Dublin Institute of Technology, Dublin 1, Ireland. +353
22 87 0995 006, Email: gary.henehan@dit.ie

23

24 **Acknowledgements:** This work was supported by a Dublin Institute of Technology Fiosraigh Award
25 to P. Shanahan.

26 **Abstract**

27 Methylxanthines are the most widely consumed drugs in the world and evidence of their health
28 benefits has been growing in recent years. Primary Amine Oxidase (PrAO) has been recognised as a
29 therapeutic target for amelioration of inflammatory, vascular and neurodegenerative diseases.
30 Previous work in our laboratories showed that caffeine inhibited Bovine PrAO with a K_i of 1.0mM
31 using benzylamine as substrate.

32 This study aimed to extend our previous work and explore the possibility that related
33 methylxanthines might influence PrAO activity. While paraxanthine, theophylline and 7-
34 methylxanthine had little effect on PrAO, theobromine was a noncompetitive inhibitor with a K_i of
35 $276 \pm 44 \mu\text{M}$. The specific structural elements of methylxanthines that are required for inhibition allow
36 us to suggest that their binding site on PrAO may be a target for therapeutics. The health benefits
37 associated with dietary methylxanthine consumption could involve PrAO inhibition.

38

39 **Practical Applications**


40 Inhibition of PrAO by methylxanthines may be significant in conferring health benefits. The design of
41 PrAO inhibitors based on the structural motifs identified in this study (N-methylation at specific
42 locations) is indicated. Existing therapeutics based on a core xanthine structure can be evaluated for
43 their effects on PrAO. Moreover, PrAO inhibition must be considered as a potential mediator of the
44 beneficial health effects of some methylxanthines. If inhibition in human tissues is comparable to, or
45 greater than, that found in these studies it points to an important role for these compounds in
46 human health.

47

48 **Introduction**

49 Caffeine, a methylxanthine, is among the most world's most widely consumed drugs. In recent years,
50 evidence of health benefits associated with consumption of caffeine and other methylxanthines has
51 been accumulating (Monteiro et al., 2016, Furman et al., 2017, Franco et al., 2013). These benefits
52 range from lowering of inflammation to the prevention of neurodegenerative disease (Chrysant
53 (2017), Kolahdouzan M and Hamadeh (2017). The effects of methylxanthines are primarily thought
54 to be due to their binding to adenosine receptors (Monteiro et al., 2016, Salomone et al., 2017).

55 Primary Amine Oxidase (PrAO) is a copper-containing transmembrane glycoprotein that catalyses
56 the following reaction:



58 It contains a cytoplasmic domain, a transmembrane segment and an extracellular domain. In the
59 vascular endothelium the extracellular domain may be cleaved off to give rise to a circulating form
60 found in plasma. In some tissues, the membrane form acts as a Vascular Adhesion Protein (VAP-1)
61 which is involved in the migration of leukocytes through the vascular endothelium at sites of
62 inflammation (Pannecoeck et al., 2015). This extravasion process requires the amine oxidase activity
63 catalyzed by PrAO to be intact (Noonan et al., 2013). Both the circulating plasma form and the
64 membrane associated PrAO are active in amine oxidation and their endogenous substrates include
65 methylamine and aminoacetone (see Lyles, 1996). These substrates are converted by PrAO to the
66 toxic aldehydes formaldehyde and methylglyoxal respectively: such aldehydes can crosslink proteins
67 *in vivo* giving rise to vascular damage (e.g. Unzeta et al., 2007). Finally, it has been shown that H₂O₂
68 generated by PrAO has a signalling role in the regulation of glucose uptake (see McDonald et al.,
69 2007).

70 Raised levels of PrAO are seen in a number of disease states including diabetes, Alzheimer's disease
71 and inflammation (Pannecoeck et al., 2015). The multiplicity of roles for PrAO in diverse processes
72 has made it an important therapeutic target (O'Sullivan et al., 2004). Inhibitors of PrAO have been

73 reported and its inhibition is known to have anti-inflammatory effects and to positively influence
74 vascular health, neurodegenerative disease progress and lung fibrosis among other conditions
75 (Horváth et al., 2017, Jarnicki et al., 2017).

76 Previous studies in these laboratories explored the inhibition of PrAO by amine compounds in food
77 and drugs and showed that caffeine inhibited bovine PrAO with a K_i of 1.0mM (Olivieri et al., 2011,
78 Olivieri and Tipton, 2011). A subsequent study (Che et al., 2012) showed that caffeine
79 administration to rats inhibited PrAO activity in serum, brain and adipose tissue and raised the
80 possibility that caffeine could be used in treating PrAO-associated disease. Trials assessing the
81 impact of caffeine on PrAO activity in human subjects have been considered but have not yet been
82 initiated (see <https://clinicaltrials.gov/ct2/show/NCT02098785>). The ability of dietary caffeine to
83 inhibit PrAO *in vivo* is highly significant and points to the possibility that ingested food compounds
84 might influence PrAO in humans in a similar manner to that seen in rat tissues (Che et al., 2012).

85 Recently, a study in human adipose tissue found that phenolic compounds in food blocked the
86 downstream effects of H_2O_2 produced by PrAO albeit without directly inhibiting PrAO activity (Les et
87 al., 2016). It is plausible that food components could be responsible for modulating the activity of
88 PrAO and that such modulation might be a significant health benefit for people on a diet enriched in
89 PrAO inhibiting components.

90 While our previous findings showed caffeine to be a PrAO inhibitor there is no information in the
91 literature concerning PrAO inhibition by other methylxanthines. It was, therefore, of interest to
92 examine whether caffeine-related compounds might contribute to modulation of PrAO activity. In
93 this study we examined theobromine, paraxanthine, theophylline, 7-methylxanthine and their
94 derivatives as modulators of bovine PrAO activity. Caffeine is found in the diet mainly in tea and
95 coffee and as a component of energy drinks (Olivieri et al., 2011, Olivieri A and Tipton 2011).
96 Theobromine and theophylline are ingested in tea and chocolate respectively (Monteiro et al.,

97 2016); paraxanthine is the major metabolite of caffeine in human tissues and 7-methylxanthine is
98 the major paraxanthine metabolite (Furman et al., 2017).

99 **Materials and Methods**

100 *Source of reagents:* Bovine plasma PrAO was obtained from Langanbach Services Ltd, Bray, Ireland.

101 Other chemicals used in this study were obtained from Sigma-Aldrich unless otherwise indicated.

102 *Standard enzyme assay:* PrAO activity was determined by following H₂O₂ production at 498 nm, by
103 the method of Holt and Palcic (2006), in the presence of 5.0 mM benzylamine. The chromogenic
104 solution for the detection of H₂O₂ contained 1 mM vanillic acid, 0.5 mM 4-aminoantipyrine and
105 horseradish peroxidase (4 U/ml) in a 'physiological' HEPES buffer system (100 mM HEPES, 280 mM
106 NaCl, 10 mM KCl, 4 mM CaCl₂, 2.8 mM MgCl₂). The pH of the buffer was adjusted to 7.4 with 0.1 M
107 NaOH. Assays were carried out in a reaction volume of 300 µl in 96-well microtitre plates, at 37⁰C,
108 using a SpectraMax 340PC plate reader (Molecular Devices, Inc. Sunnyvale, CA 94089-1136, USA).
109 Control assays for the coupling system, in the presence of 10 µM H₂O₂, 1 mU/ml HRP but without
110 PrAO, showed that none of the compounds affected the chromogenic detection system. Each
111 compound was assayed in triplicate, at a final concentration of 0.5 or 1.0 mM.

112 *Data analysis and curve fitting:* Data for each methylxanthine tested as an inhibitor was obtained in
113 three separate experiment each conducted in triplicate. Data are reported as mean +/- standard
114 error of the mean. Dunnett's test was used to assess the statistical significance of differences
115 between test and control data.

116 Kinetic data were directly fitted by non-linear regression to the Michaelis-Menten equation by Graph
117 Pad Prism, version 5. Replots were fitted by linear regression. Double-reciprocal plots are shown for
118 illustrative purposes only.

119

120 **Results**

121 The structures of the compounds tested in this study are shown in Figure 1. The effect of caffeine,
122 paraxanthine, theophylline, theobromine and 7-methylxanthine on PrAO at fixed concentrations of
123 500 μ M and 1.0mM was examined using the standard assay (Figure 2).

124 **.....FIGURE 1 HERE.....**

125 Of the five methylxanthines tested only caffeine and theobromine showed substantial inhibition of
126 PrAO: surprisingly, the other compounds tested; theophylline, paraxanthine and 7-methylxanthine
127 had relatively little effect.

128 **.....FIGURE 2 HERE.....**

129 Since caffeine is derived from xanthine we decided to test xanthine and related compounds as PrAO
130 inhibitors. Figure 3 shows that neither xanthine, its metabolites hypoxanthine and uric acid, or
131 imidazole had a significant inhibitory effect on PrAO activity at the concentrations used.

132 **.....FIGURE 3 HERE.....**

133 Since theobromine was the only compound showing activity comparable to that of caffeine its
134 interaction with PrAO it was examined in greater detail. The pattern of inhibition with theobromine
135 was examined using benzylamine as substrate (Figure 4a). A noncompetitive pattern of inhibition
136 was observed and a K_i of $276\pm 44\mu$ M was estimated from a slopes replot of this data (Fig 4b).

137 **.....FIGURE 4 HERE.....**

138 This pattern of inhibition is similar to that seen with caffeine (Olivieri and Tipton K. (2011) although
139 the K_i estimated was significantly lower for theobromine than for caffeine.

140

141

142 **Discussion**

143 These findings, for the first time, identify theobromine as a modulator of bovine PrAO activity. This
144 expands the range of compounds that can influence this important enzyme. Theobromine, which is
145 a constituent of cocoa as well as a caffeine metabolite in humans, is a more effective inhibitor than
146 caffeine. Theobromine has a longer plasma half-life than caffeine and is considered less active in the
147 central nervous system and therefore is associated with less toxic side effects (Monteiro et al.,
148 2017). The longer half-life of theobromine may mean its effects will be more prolonged than those
149 of caffeine. It is also important to note that theobromine may be formed from caffeine breakdown
150 *in vivo* (Oñatibia-Astibia et al., 2017).

151 In humans, the plasma concentration of theobromine has been reported to be as high as 63µM
152 following the consumption of chocolate (Oñatibia-Astibia et al., 2017). The relationship between K_i
153 and inhibitor concentration for a noncompetitive inhibitor is given by equation 1:

154

$$V_{max\ app} = \frac{V_{max}}{1 + \frac{I}{K_i}}$$

155 *Equation 1. Noncompetitive inhibition: The equation shows the relationship between maximum*
156 *velocity, $V_{max\ app}$ (the apparent maximum velocity), in the presence of an inhibitor (I) and the*
157 *maximum velocity in the absence of an inhibitor (V_{max}). The term K_i is the inhibitor binding constant.*

158

159 Using 63µM for [I] and 276 µM for K_i we can calculate that $V_{max\ app} = 81\%$ of V_{max} . Thus, the
160 maximum rate of PrAO in the presence of 63µM theobromine is reduced by approximately 20%.

161 A study of plasma PrAO levels in human type 1 diabetes showed PrAO activity of 1049 ± 294 mU/L
162 versus an activity of 749 ± 204 mU/L in control subjects (mean \pm SD; $p < 0.00001$) (see Januszewski et
163 al., 2014). Thus, a difference of roughly 30% in PrAO activity correlated with renal dysfunction and
164 vascular inflammation. A similar level of PrAO elevation was observed in hypertensive heart disease
165 (Marinho et al, 2010). Clearly, relatively modest increases in the level of this enzyme correlate with

166 disease progression. In this context the level of inhibition observed in these studies is potentially
167 significant.

168 The net effect of methylxanthines on PrAO activity may be complex and difficult to determine with
169 accuracy since these compounds may derive directly from various components of the diet or arise as
170 metabolites of caffeine. Assessing the combined effect of such compounds will require animal or
171 preferably human trials. It is also worth noting that, in recent years, theobromine supplements have
172 become widely available online as powders, capsules and pills for treatment of weight loss, blood
173 pressure and cancer, among other conditions.

174 *Structure activity relationships:* Of particular importance was the observation that none of the
175 methylxanthines besides caffeine and theobromine showed significant inhibition. This allowed us to
176 identify structural features necessary for inhibition. Thus, 7-methylxanthine, a caffeine derivative
177 lacking a methyl group at position 3, shows little inhibition. Similarly, theophylline, lacking the
178 methyl group at position 7, is relatively ineffective as an inhibitor. It is clear that methylation of
179 positions 3 and 7 on xanthine are necessary for inhibition. The lack of significant inhibition by these
180 closely related compounds suggests that other elements of the xanthine structure contribute little to
181 inhibitor binding. The lower K_i for theobromine relative to caffeine may be due to the formation of
182 hydrogen bonds between the nitrogen in position 1 and amino acid side chains on PrAO. Imidazole
183 was reported to be an inhibitor of PrAO at high concentrations (Elovaara et al., 2016) but at the
184 highest level used herein (1.0mM) showed only mild inhibition (Figure 3).

185 *Methylxanthine binding site:* The pattern of inhibition is noncompetitive, implying that theobromine
186 does not directly block substrate binding but still affects substrate turnover. This pattern is normally
187 interpreted as the binding of inhibitor to a site other than the active site (Figure 5). Thus, the
188 inhibitor may bind to both free enzyme *and* the enzyme substrate complex. However, the ping-pong
189 mechanism of PrAO-catalysed amine oxidation means that ligands may bind to both oxidized and
190 reduced forms of this enzyme yielding complex kinetic plots (see Holt et al., 2008). Noncompetitive

191 inhibition might be expected if the methylxanthines bind within the substrate entrance channel of
192 either oxidised or reduced forms of PrAO. A similar noncompetitive pattern of inhibition was
193 observed with caffeine when benzylamine was the substrate although a mixed pattern of inhibition
194 was seen when methylamine was the substrate (Olivieri and Tipton, 2011).

195 **.....FIGURE 5 HERE.....**

196 An imidazoline binding site on PrAO has been indicated in previous studies (Holt et al., 2008) and
197 two imidazole binding sites have been identified on a crystal structure of human PrAO (Elovaara et
198 al., 2011). The crystal structure showed imidazole bound to the topaquinone (TPQ) cofactor of both
199 the oxidised and reduced forms of PrAO. It is possible that one of these sites might bind the
200 methylxanthines of this study. Theobromine and caffeine presumably interact via hydrogen bond
201 formation with residues of PrAO. Comparison with the other structures considered herein shows
202 that inhibition is quite specific requiring the particular pattern of N-methylation only found in
203 caffeine and theobromine.

204 The well-known positive effects of caffeine and theobromine on vascular health, inflammation and
205 neurodegenerative disease have been variously attributed to binding at adenosine receptors,
206 phosphodiesterase inhibition, binding to GABA receptors or calcium regulation (Monteiro et al.,
207 2016). Inhibition of PrAO has not been considered as significant in this process; however, the
208 benefits ascribed to methylxanthines mirror those associated with PrAO inhibition. It is conceivable
209 that modulation of PrAO activity by ingested methylxanthines and their metabolites might
210 contribute to lowering PrAO activity *in vivo*. This in turn might account for the known dietary
211 advantage associated with consumption of compounds in this class.

212 A great deal of effort has been directed towards the development of specific inhibitors of PrAO but
213 efforts have been hampered by a lack of selectivity or because inhibitors contain highly reactive
214 structural elements (see O'Rourke et al., 2008). It is possible that the caffeine/theobromine binding

215 site identified here might offer an attractive target for PrAO inhibitor design since it can inhibit
216 activity without affecting substrate affinity: a noncompetitive inhibitor, unlike a competitive
217 inhibitor, will not be affected by fluctuations in the physiological concentration of substrates
218 available to PrAO.

219 It is worth noting that caffeine derivatives have been explored previously in the treatment of
220 neurodegenerative disease (Petzer and Petzer 2015, Pohanka 2015). For example, substitution at
221 position 8 in caffeine to give 8-chlorostyrylcaffeine, produces a powerful reversible inhibitor of
222 monoamine oxidase B (Binda et al, 2006). Likewise, substitutions on the nitrogen atom at position 1
223 of theobromine gives rise to the anti-inflammatory lisofylline and the antihistamine pentoxifylline
224 (Pascal et al, 1985). Di-substituted derivatives such as the 3, 8 substituted compounds bamiphylline,
225 naxifylline and rolofylline, with increased solubility, have also been investigated as cardioprotective
226 drugs (Szentmiklósi et al, 2011). The effects of many of these drugs on MAO and PrAO have not been
227 assessed although there is evidence that the inhibition of both enzymes may be beneficial in the
228 management of neurodegenerative diseases, in combatting oxidative stress (Liu et al, 2010) and in
229 the treatment of obesity (Carpéné et al, 2007). Thus, theobromine may provide a useful skeleton for
230 the development of more powerful drugs and multi-target directed ligands. These findings provide a
231 strong impetus to extend these studies to human tissues.

232

233 ***Conflict of Interest***

234 On behalf of all authors, the corresponding author states that there is no conflict of interest.

235 **References**

- 236 Binda C, Hubálek F, Li M, Castagnoli N, Edmondson DE & Mattevi A. (2006) Structure of the human
237 mitochondrial monoamine oxidase B: new chemical implications for neuroprotectant drug design.
238 *Neurology*, 67(Suppl 2): S5-7.
- 239 Carpéné C, Iffiú-Soltesz Z, Bour S, Prévot D, Valet P. (2007) Reduction of fat deposition by combined
240 inhibition of monoamine oxidases and semicarbazide-sensitive amine oxidases in obese Zucker rats.
241 *Pharmacol Res.*, 56, 522-530.
- 242 Che B, Wang L, Zhang Z, Zhang Y, Deng Y. (2012) Distribution and accumulation of caffeine in rat
243 tissues and its inhibition on semicarbazide-sensitive amine oxidase. *Neurotoxicology*, 33, 1248-53.
- 244 Chrysant SG. (2017) The impact of coffee consumption on blood pressure, cardiovascular disease
245 and diabetes mellitus. *Expert Rev Cardiovasc Ther.*, 15, 151-156.
- 246 Elovaara H, Kidron H, Parkash V, Nymalm Y, Bligt E, Ollikka P, Smith DJ, Pihlavisto M, Salmi M,
247 Jalkanen S, Salminen TA. (2011) Identification of two imidazole binding sites and key residues for
248 substrate specificity in human primary amine oxidase AOC3. *Biochemistry*. 50(24):5507-20.
- 249 Elovaara H, Parkash V, Fair-Mäkelä R, Salo-Ahen OM, Guédez G, Bligt-Lindén E, Grönholm J, Jalkanen
250 S, Salminen TA. (2016) Multivalent Interactions of Human Primary Amine Oxidase with the V and C22
251 Domains of Sialic Acid-Binding Immunoglobulin-Like Lectin-9 Regulate Its Binding and Amine Oxidase
252 Activity. *PLoS One*, 11, e0166935.
- 253 Franco R, Oñatibia-Astibia A, Martínez-Pinilla E. (2013) Health Benefits of Methylxanthines in Cacao
254 and Chocolate. *Nutrients*, 5, 4159-4173.
- 255 Furman D, Chang J, Lartigue L, Bolen CR, Haddad F, Gaudilliere B, Ganio EA, Fragiadakis GK, Spitzer
256 MH, Douchet I, Daburon S, Moreau JF, Nolan GP, Blanco P, Déchanet-Merville J, Dekker CL, Jojic V,

257 Kuo CJ, Davis MM, Faustin B. (2017) Expression of specific inflammasome gene modules stratifies
258 older individuals into two extreme clinical and immunological states. *Nat Med.*, 23,174-184.

259 Holt A, Smith DJ, Cendron L, Zanotti G, Rigo A, Di Paolo ML. (2008) Multiple binding sites for
260 substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences. *Mol*
261 *Pharmacol.*, 73, 525-38.

262 Holt A, Palcic MM. (2006) A peroxidase-coupled continuous absorbance plate-reader assay for flavin
263 monoamine oxidases, copper-containing amine oxidases and related enzymes. *Nat Protoc.*, 1, 2498-
264 505.

265 Horváth Á, Menghis A, Botz B, Borbély É, Kemény Á, Tékus V, Csepregi JZ, Mócsai A, Juhász T, Zákány
266 R, Bogdán D, Mátyus P, Keeble J, Pintér E, Helyes Z. (2017) Analgesic and Anti-Inflammatory Effects
267 of the Novel Semicarbazide-Sensitive Amine-Oxidase Inhibitor SzV-1287 in Chronic Arthritis Models
268 of the Mouse. *Sci Rep.*, 7:39863.

269 Januszewski AS, Mason N, Karschimkus CS, Rowley KG, Best JD, O'Neal DN, Jenkins AJ. (2014) Plasma
270 semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal
271 function but not to glycaemia. *Diab Vasc Dis Res.* (4):262-269.

272 Jarnicki AG, Schilter H, Liu G, Wheeldon K, Essilfie AT, Foot JS, Yow TT, Jarolimek W, Hansbro PM.
273 (2016) The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features
274 of chronic obstructive pulmonary disease in a mouse model. *Br J Pharmacol.*, 173, 3161-3175.

275 Kolahdouzan M, Hamadeh MJ. (2017) The neuroprotective effects of caffeine in neurodegenerative
276 diseases. *CNS Neurosci Ther.*, 23, 272-290.

277 Les F, Deleruyelle S, Cassagnes LE, Boutin JA, Balogh B, Arbones-Mainar JM, Biron S, Marceau P,
278 Richard D, Nepveu F, Mauriège P, Carpéné C. (2016) Piceatannol and resveratrol share inhibitory

279 effects on hydrogen peroxide release, monoamine oxidase and lipogenic activities in adipose tissue,
280 but differ in their antilipolytic properties. *Chem Biol Interact.*, 258,115-25.

281 Liu YH, Wu WC, Lu YL, Lai YJ, Hou WC. (2010) Antioxidant and Amine Oxidase Inhibitory Activities of
282 Hydroxyurea. *Biosci. Biotechnol. Biochem.*, 74,1256-1260.

283 Lyles GA. (1996) Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases:
284 biochemical, pharmacological and toxicological aspects. *Int J Biochem Cell Biol.* 28:259-74.

285 Marinho C, Arduíno D, Falcão LM, Bicho M. (2010) Alterations in plasma semicarbazide-sensitive
286 amine oxidase activity in hypertensive heart disease with left ventricular systolic dysfunction. 29 (1):
287 37-47.

288 McDonald A, Tipton K, O'Sullivan J, Olivieri A, Davey G, Coonan AM, Fu W. (2007) Modelling the roles
289 of MAO and SSAO in glucose transport. *J Neural Transm (Vienna)*., 114, 783-6.

290 Monteiro JP, Alves MG, Oliveira PF, Silva BM. (2016) Structure-Bioactivity Relationships of
291 Methylxanthines: Trying to Make Sense of All the Promises and the Drawbacks. *Molecules*, 21(8). pii:
292 E974.

293 Noonan, T., Lukas, S., Peet, G. W., Pelletier, J., Panzenbeck, M., Hanidu, A., ... Modis, L. K. (2013).
294 The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. *American Journal*
295 *of Clinical and Experimental Immunology*, 2(2), 172–185.

296 Olivieri A, Rico D, Khiari Z, Henehan G, O'Sullivan J, Tipton K. (2011) From caffeine to fish waste:
297 amine compounds present in food and drugs and their interactions with primary amine oxidase. *J*
298 *Neural Transm (Vienna)*, 118, 1079-89.

299 Olivieri A, Tipton K. (2011) Inhibition of bovine plasma semicarbazide-sensitive amine oxidase by
300 caffeine. *J Biochem Mol Toxicol.*, 25, 26-7.

301 Oñatibia-Astibia A, Franco R, Martínez-Pinilla E. (2017) Health benefits of methylxanthines in
302 neurodegenerative diseases. *Mol Nutr Food Res.*, 61, 6-10.

303 O'Rourke AM, Wang EY, Miller A, Podar EM, Scheyhing K, Huang L, Kessler C, Gao H, Ton-Nu HT,
304 Macdonald MT, Jones DS, Linnik MD. (2008) Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-
305 methoxybenzyl) allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive
306 amine oxidase activity. *J Pharmacol Exp Ther.*, 324, 867-75.

307 O'Sullivan J, Unzeta M, Healy J, O'Sullivan MI, Davey G, Tipton KF. (2004) Semicarbazide-sensitive
308 amine oxidases: enzymes with quite a lot to do. *Neurotoxicology*, 25, 303-15.

309 Pannecoeck R, Serruys D, Benmeridja L, Delanghe JR, van Geel N, Speeckaert R, Speeckaert MM.
310 (2015) Vascular adhesion protein-1: Role in human pathology and application as a biomarker. *Crit*
311 *Rev Clin Lab Sci.*, 52, 284-300.

312 Pascal JC, Beranger S, Pinhas H, Poizot A & Désiles JP. (1985) New antihistaminic theophylline or
313 theobromine derivatives. *J. Med. Chem.*, 28, 647-652.

314 Petzer JP & Petzer (2015) A Caffeine as a lead compound for the design of therapeutic agents for the
315 treatment of Parkinson's disease. *Curr. Med. Chem.*, 22, 975-988.

316 Salomone F, Galvano F, Li Volti G. (2017) Molecular Bases Underlying the Hepatoprotective Effects
317 of Coffee. *Nutrients*, 9, 85-95.

318 Pohanka M. (2015) The perspective of caffeine and caffeine derived compounds in therapy. *Bratisl*
319 *Lek Listy.*, 116, 520-530.

320 Szentmiklósi AJ, Cseppentő A, Gesztelyi R, Zsuga J, Körtvély A, Harmati G & Nánási PP. (2011)
321 Xanthine derivatives in the heart: blessed or cursed? *Curr. Med. Chem.*, 18, 3695-3706.

322 Tipton KF, Boyce S, O'Sullivan J, Davey GP, Healy J. (2004) Monoamine oxidases: certainties and
323 uncertainties. *Curr Med Chem.*, (15), 1965-82.

324 Unzeta M, Solé M, Boada M, Hernández M. (2007) Semicarbazide-sensitive amine oxidase (SSAO)
325 and its possible contribution to vascular damage in Alzheimer's disease. J Neural Transm (Vienna).
326 114(6):857-62.

327

328

329 **Figure Legends**

330 *Figure 1: Structures of the methylxanthines considered in this study. These naturally-occurring compounds are all N-*
331 *methylated derivatives of xanthine.*

332 *Figure 2. Inhibition of PrAO activity by methylxanthines. Assays were carried out at 37⁰C and pH 7.4 as described in*
333 *materials and methods. The control was a standard assay of PrAO in the presence of 5.0 mM benzylamine. The data shown*
334 *are the mean ± SEM (n=3). Asterisks denote a significant difference between treatments and the control (*P ≤ 0.05; **P ≤*
335 *0.01; ***P ≤ 0.001) using Dunnett's test.*

336 *Figure 3. Effect of xanthine and related compounds on PrAO activity. Assays were carried out at 37⁰C and pH 7.4 as*
337 *described in materials and methods. The control was a standard assay of PrAO in the presence of 5.0 mM Benzylamine. All*
338 *data are the mean±SEM of three separate determinations. Asterisks denote a significant difference between treatments*
339 *and the control (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001) using Dunnett's test.*

340 *Figure 4. (a) Pattern of inhibition of PrAO by theobromine. Assays were carried out as indicated in the methods section.*
341 *Benzylamine concentration was varied between 1.0 and 5.0mM at various concentrations of caffeine: 0, 100, 200, 300, 400,*
342 *500, 600µM. The Lineweaver Burk plots are shown for illustrative purposes only: each data set was fitted to a rectangular*
343 *hyperbola and Kmapp and Vmax estimated by non-linear regression with the aid of Graph Pad Prism 5.0. (b) A replot of*
344 *slopes (Kmapp/Vmax) for each line in Fig 4a versus theobromine concentration was used to estimate Ki. A Ki of 276± 44 µM*
345 *mean ± SEM (n=3) was estimated.*

346 *Figure 5. Noncompetitive inhibition mechanism. Where E represents enzyme, S, the substrate, P the product and I the*
347 *inhibitor. The constant K for substrate binding is unaffected by the binding of inhibitor. The inhibitor binding constant is*
348 *denoted Ki. In this mode of inhibition the inhibitor binds equally to free enzyme and enzyme-substrate complex (ES) causing*
349 *a decrease in Vmax but not affecting Km. The binding of inhibitor is considered to be independent of substrate binding.*

350

351


352

353


354

355


Figure 1




CAFFEINE




PARAXANTHINE



THEOPHYLLINE



THEOBROMINE



7-METHYLSANTHINE

Figure 2




Figure 3




Figure 4a




Figure 4b




Figure 5

